PATIENT ALERT: Information regarding Coronavirus (COVID-19).  

Breast Cancer Trials

Breast Cancer Trials

  • MERCK KEYLYNK MK7339-009

    An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)(KEYLYNK-009)

    Available at 3 locations

    View Details

  • USO 18282

    Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) In Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens (IMMU-132-09)

    Available at 1 location

    View Details

  • USO 17026

    A Phase II, Multicenter, Open-Label, Three-Cohort, Noncomparative Study To Assess The Efficacy And Safety Of Alpelisib Plus Fulvestrant Or Letrozole In Patients With PIK3CA Mutant,Hormone Receptor (HR) Positive, HER2-Negative Advanced Breast Cancer (Abc), Who Have Progressed On Or After Prior Treatments (CBYL719X2402)

    Available at 1 location

    View Details

  • USO 19009

    A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer (ODO-TE-B202)

    Available at 3 locations

    View Details

  • USO 18232

    A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Breast or Gynecologic Malignancies (AB928CSP0002)

    Available at 1 location

    View Details

  • USO 17188

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

    Available at 5 locations

    View Details

  • Alliance A011502 (ABC Trial)

    A Randomized Phase III Double Blinded Placebo-Controlled Trial Of Aspirin As Adjuvant Therapy For Node-Positive, HER2 Negative Breast Cancer

    Available at 6 locations

    View Details